Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI

March 6, 2017 updated by: William A. Bauman, M.D., James J. Peters Veterans Affairs Medical Center

Effects of Vitamin D Deficiency and Its Replacement on Pulmonary and Endocrine Function in Persons With SCI

Studies have shown that individuals who have suffered a spinal cord injury are at an increased risk of Vitamin D deficiency compared to able-bodied individuals. It has recently been shown that Vitamin D deficiency is linked to a large number of diseases and conditions, including chronic lung disease, vascular problems, and insulin resistance. If this common nutritional deficiency is proven to be the cause of some of these diseases and conditions in persons with SCI, then it may easily be remedied with a cheap and effective therapeutic approach: vitamin D replacement therapy. Because of the high prevalence of vitamin D deficiency in persons with SCI, this therapy alone or in combination with other treatment options will be expected to significantly improve overall well being in the SCI population, decrease hospitalization rate, and the lower the financial burden of care.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Vitamin D deficiency is prevalent in individuals with Spinal Cord Injury (SCI). Recent studies have linked vitamin D with the prevention and/or treatment of a wide range of diseases, including chronic lung diseases. Patients with chronic lung diseases appear to be at increased risk for vitamin D deficiency for reasons that are not clear. Chronic lung diseases such as asthma and chronic obstructive lung disease (COPD) have been linked to vitamin D on a genetic basis. A recent observational study found a significant association between vitamin D deficiency and decreased pulmonary function in a large able-bodied population. The exact mechanisms involved have not been identified, but it has been postulated that vitamin D possesses a range of anti-inflammatory properties involving modulation of oxidative stress, or, possibly, protease/antiprotease balance and tissue damage/repair, mechanisms that have been shown to be important in the pathogenesis of chronic lung diseases. The relationship between vitamin D and the immune system is of utmost importance given that individuals with high cervical lesions express many obstructive aspects of pulmonary physiology commonly observed in individuals with asthma, in whom airway inflammation represents an underlying pathophysiological mechanism.

In addition to a high prevalence of vitamin D deficiency, persons with SCI have a higher prevalence of insulin resistance (IR), impaired glucose tolerance (IGT) and diabetes mellitus (DM). In the general population, vitamin D deficiency has been shown to be associated with IR, IGT and DM. If treatment of vitamin D deficiency in persons with SCI is shown to be associated with improvement in insulin sensitivity and reductions in impaired glucose tolerance or DM, then progression to more severe carbohydrate disorders may be delayed or prevented.

Study Type

Interventional

Enrollment (Actual)

88

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Bronx, New York, United States, 10468
        • James J Peters VA Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Part 1: Screening for Vitamin D Deficiency

Inclusion Criteria:

  • Between the ages of 18 and 75,
  • Chronic (>1 year) SCI; tetraplegia (C3-8), paraplegia, (T1-6)

Exclusion Criteria:

  • Acute illness
  • Acute drug or alcohol use
  • Lack of mental capacity to give informed consent,
  • Pregnancy,
  • Currently receiving Vitamin D supplementation.

Part 2A: Vitamin D and Pulmonary Function

Inclusion Criteria:

  • Between the ages of 18 and 75,
  • Chronic SCI (>1 year, C3-T6)
  • Vitamin D deficiency as defined as a value <20 ng/ml.

Exclusion Criteria:

  • Smoking, active or history of smoking during life time,
  • Any history of blast injuries to the chest,
  • Active respiratory disease,
  • Pregnancy,
  • Lack of mental capacity to give informed consent.
  • Recent (within 3 months) respiratory infection.
  • Receiving medications known to alter airway caliber.
  • Acute drug or alcohol use,
  • Currently receiving Vitamin D supplementation > 1000 units/day.

Part 2B: Vitamin D, Carbohydrate Metabolism, and Insulin Resistance

Inclusion Criteria:

  • Between the ages of 18 and 75,
  • Chronic SCI (>1 year, C3-T6)
  • Vitamin D deficiency as defined as a value <20 ng/ml,
  • Insulin Resistance (IR), Impaired glucose tolerance (IGT), and/or Diabetes Mellitus (DM).

Exclusion Criteria:

  • Pregnancy,
  • Problems with the kidneys,
  • Lack of mental capacity to give informed consent,
  • Acute drug or alcohol use,
  • Currently receiving Vitamin D supplementation > 1000 units/day.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Screening Study
To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
Experimental: Pulmonary Arm

Vitamin D3 Supplementation and Pulmonary Function:

  1. To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).
  2. To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels).
4000 IU/day or 2000 IU/day for 12 weeks
Other Names:
  • Cholecalciferol
Experimental: Endocrine Arm

Vitamin D3 Supplementation and Endocrine Function:

To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR.

4000 IU/day or 2000 IU/day for 12 weeks
Other Names:
  • Cholecalciferol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of SCI participants with vitamin D deficiency
Time Frame: Screening study (1 visit, 2 hours)
Vitamin D levels will be obtained during screening.
Screening study (1 visit, 2 hours)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary function improvement as measured by PFTs in SCI with increased vitamin D levels
Time Frame: Change from baseline at 6 months
Pulmonary function change will be measured in vitamin D deficient SCI subjects by spirometry and body plethysmography at baseline, 3 months, and 6 months.
Change from baseline at 6 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pulmonary function improvement as measured by inflammation in SCI with vitamin D supplementation.
Time Frame: Change from baseline at 6 months
Pulmonary function change will be measured in vitamin D deficient SCI subjects by biomarkers of inflammation, such as FeNO, pH, and 8-isoprostane, at baseline, 3 months, and 6 months.
Change from baseline at 6 months
Impaired glucose tolerance (IGT) improvement in SCI with vitamin D supplementation
Time Frame: Change from baseline at 6 months
Vitamin D deficient SCI subjects with IGT and/or IR will undergo vitamin D replacement therapy. Glucose and insulin levels will be measured at baseline, 3 months, and 6 months.
Change from baseline at 6 months
Musculoskeletal pain improvement with vitamin D supplementation
Time Frame: Change from baseline at 6 months
Vitamin D deficient SCI subjects will complete a pain survey at baseline, 3 months, and 6 months to assess musculoskeletal pain and how it may improve with vitamin D supplementation.
Change from baseline at 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: William Bauman, M.D., James J Peters VA Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

December 5, 2013

First Submitted That Met QC Criteria

March 26, 2014

First Posted (Estimate)

March 31, 2014

Study Record Updates

Last Update Posted (Actual)

March 7, 2017

Last Update Submitted That Met QC Criteria

March 6, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • BAU-11-092

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.